WHAT IS INTERCEPT-MDS?

EXPLORING CELL-TO-CELL HETEROGENEITY AND EXPLOITING EPIGENETIC REGULATION FOR THE INTERCEPTION OF MYELOID DISEASE CELLS

INTERCEPT-MDS is an Innovative Training Network funded by the European Union’s Horizon 2020 research and innovation programme.

Born from the LifeTime Initiative, the aim of INTERCEPT-MDS is to train Europe’s first experts at the doctorate level in the novel field of disease interception: treating a disease before it fully develops by removing altered cells.

INTERCEPT-MDS brings together 10 European public and private institutions in a European network of experts in leukaemia, epigenetics and single-cell genomics.

Through a multidisciplinary and multisectoral approach, INTERCEPT-MDS will study disease interception in the context of clonal myeloid diseases, using single-cell genomic methods to identify altered cells and test epigenetic perturbations to specifically remove them.

Image modified from Rajewsky, N. et al. LifeTime and improving European healthcare through cell-based interceptive medicine. Nature (2020). 

NEWS

05.06.2023

In June we feature our fifth ESR of the month: Sven De Pourcq!

Sven works in Valeria Santini’s lab at the Università degli Studi di Firenze, Florence, Italy. . Here, he is studying studying methylation patterns in patients treated with hypomethylating agents with the aim to find biomarker and drug synergies.

Don’t miss the 5 Ws of Svens’s research, here:  

 

TWITTER